Table 1.
Characteristics of studies included in the present study.
| Author, year | Participants | Mean age | Participants (M/F) | Intervention | Frequency, duration, and intensity of aerobic exercise | Outcomes/measure |
|---|---|---|---|---|---|---|
| Cetin et al., 2010 | Healthy elderly | 70.3 | 29 (24/5) | T: walking C: no training |
50min/day, 3days/week, 6months, and 60–75% HRmax | VE/Spectrofluorometrically TAC/Colorimetric assay kit |
| Mohammadi et al., 2018 | Overweight elderly men | 72.4 | 24 (24/0) | T: aerobic exercises C: maintain their usual lifestyle |
45–60min/day, 3days/week, 8weeks, and 90–95% HRmax | NO/Zebra Kit |
| Hejazi et al., 2019 | Elderly healthy women | 65.5 | 21 (0/21) | T: aerobic exercises C: maintain their usual lifestyle |
45–60min/day, 4days/week, 8weeks, and 50–70% HRmax | 8-OHdG/ELISA |
| Groussard et al., 2015 | Adults with ESKD | 67.6 | 18 (13/5) | T: specialized cycle ergometers C: no training |
30min/day, 3days/week, 3months, and 50–60% HRmax | Ox-LDL/ELISA GSH/GSSG/GSH/GSSG-412 kit SOD/Ransod Kit GPX/Ransel Kit |
| Alghadir et al., 2016 | Healthy elderly | 69.7 | 100 (70/30) | T: treadmill, bicycle, and StairMaster C: no training |
45–60min/day, 3days/week, 24weeks, and 60–70% HRmax | TAC/Colorimetric Assay Kit MDA/HPLC 8-OHdG/ELISA |
| Fatouros et al., 2004 | Elderly healthy man | 72.3 | 19 (19/0) | T: walking/jogging C: no training |
60min/day, 3days/week, 16weeks, and 50–80% HRmax | MDA/TBA 3-NT/HPLC TAC/Chemiluminescence GPX/Hitachi 2001 UV/VIS spectrophotometer |
| Osali, 2020 | Women with metabolic syndrome | 62.3 | 22 (0/22) | T: walking/running C: no training |
36–51min/day, 7days/week, 6weeks, and 65–75% HRmax | TAC/The ferric reducing ability of plasma MDA/Esterbauer and Cheeseman method |
| Xiong and Feng, 2015 | Healthy elderly | 63.4 | 40 (20/20) | T: walking C: no training |
35–45min/day, 60days | SOD, GPX, GSH, MDA |
| Liu et al., 1996 | Elderly healthy man | 64.8 | 86 (86/0) | T: Tai Chi C: no training |
60min/day, 5days/week, and 1year | SOD/Catechol Autoxidation LPO/TBA colorimetry |
| Sha, 2007 | Adults with AS | 64.1 | 40 (24/16) | T: Tai Chi C: no training |
60–120min/day, 5–7days/week, and 18months | NO/NR |
| Xie and Bai, 2014 | Adults with EH | 60–70 | 50 (25/25) | T: Tai Chi C: no training |
60min/day, 5days/week, 12weeks, and 40–60% HRmax | NO/NR |
| Shi et al., 1995 | Adults with EH | 68.2 | 32 (25/7) | T: walking/jogging/Tai Chi C: no training |
60min/day, 3years, and 70% HRmax | LPO/TBA |
| Yao et al., 2001 | Adults with hypertension | 65.8 | 41 (10/31) | T: aerobic exercises C: no training |
60min/day, 6days/week, 7weeks, and 50–60% HRmax | NO/NR |
| Zhu et al., 2008 | Elderly healthy women | 63 | 75 (0/75) | T: Wu Qin Xi C: no training |
45min/day, 16weeks, and moderate intensity | SOD/XO MDA/TBA |
| He et al., 2011 | Elderly healthy women | 62.8 | 80 (0/80) | T: Baduanjin C: no training |
45min/day, 20weeks, and moderate intensity | SOD/XO MDA/TBA |
| Zhen et al., 2014 | Adults with EH | 69.6 | 55 (29/26) | T: conventional treatment and Baduanjin C: conventional treatment |
30min/day, 5days/week, and 12weeks | NO/NR |
| Liu and Jin, 2010 | Elderly healthy women | 65.7 | 62 (0/62) | T: Yi Jinjing C: no training |
40–50min/day, 6days/week, 6months, and 60–75% HRmax | SOD/Hydroxylamine oxidation GPX/DTNB direct colorimetry MDA/TBA colorimetry |
| Wang et al., 2015 | Adults with T2DM | 64.2 | 100 (45/55) | T: Baduanjin C: no training |
60min/day, 3days/week, and 1year | 8-isoPGF2/ELISA SOD/Fluorescence |
| Yang et al., 2015 | Adults with ISH | 68.1 | 166 (59/107) | T: conventional treatment and bicycling C: conventional treatment |
30min/day, 3days/week, 20weeks, and 60–80% HRmax | NO/Greiss |
| Ma et al., 2017 | Adults with CHF | 61–78 | 110 (73/37) | T: conventional treatment and combination of aerobic activity C: conventional treatment |
30–40min/day, 4days/week, 12weeks, and 60–80% HRmax | NO/NR |
VE, vitamin E; TAC, total antioxidant capacity; NO, nitric oxide; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; ELISA, enzyme linked immunosorbent assay; ESKD, end-stage kidney disease; Ox-LDL, oxidized low-density lipoprotein; GSH/GSSG, reduced glutathione/oxidized glutathione; SOD, superoxide dismutase; GPX, glutathione peroxidase; MDA, malondialdehyde; HPLC, high performance liquid chromatography; TBA, thiobarbituric acid; 3-NT, 3-Nitrotyrosine; GPX, glutathione peroxidase; GSH, glutathione; LPO, lipid peroxide; AS, atherosclerosis; NR, nitrate reductase; EH, essential hypertension; XO, xanthine oxidase; DTNB, 5,5'-Dithiobis (2-nitrobenzoic acid); T2DM, type 2 diabetes mellitus; 8-isoPGF2, 8-iso-prostaglandin F2α; ISH, isolated systolic hypertension; and CHF, coronary heart disease with chronic heart failure.